Jennifer La PhD

Published on 9/17/2026

Yellanki M, La J, Elbers DC, Do NV, Paller CJ, Fillmore NR, Schoen MW. Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration-Resistant Prostate Cancer. Prostate. 2026 Sep 17. PMID: 42752817.

Published on 9/8/2026

Lee G, Bihn JR, Culnan JM, La J, Do NV, Myrie K, Paller CJ, Fillmore NR, Cooperberg MR. Active Surveillance Use for Favorable-Risk Prostate Cancer in a Veterans Affairs Population. JAMA. 2026 Sep 08; 336(10):884-886. PMID: 42593769.

Published on 7/16/2026

La J, Wang L, Corrigan JK, Lang D, Do NV, Brophy MT, Fillmore NR, Paller CJ. Abiraterone or Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer: A Nationwide Veterans Affairs Study. JCO Clin Cancer Inform. 2026; 10(3):e2500213. PMID: 42462188.

Published on 7/14/2026

La J, Jafari O, Nannini K, Do NV, Brophy MT, Fillmore NR, Li A. Temporal validation of the electronic health record cancer-associated thrombosis model in patients with low bleeding risk. Res Pract Thromb Haemost. 2026 Jul; 10(5):106830. PMID: 42568708.

Published on 6/2/2026

Lam BD, Ito S, Ryu J, O'Sullivan K, Potnis K, Lu R, Bidikian A, Ng DQ, Singh R, Deter A, Carfagnini C, Bechara S, Kandula M, Do N, Fillmore N, Freed JA, Patell R, La J, Goshua G. JAKPOT Prediction Rule for Erythrocytosis: External Validation and Cost-Effectiveness Analysis. Am J Hematol. 2026 Sep; 101(9):2412-2416. PMID: 42227164.

Published on 5/18/2026

He T, Zheng C, La J, Pham D, Jafari O, Strampe J, Dulberger K, Ramos-Cejudo J, Gaziano JM, Do NV, Chitalia V, Ravid K, Li A, Fillmore NR. A deep learning model to dynamically predict cancer-associated thromboembolism in large-scale healthcare systems. NPJ Digit Med. 2026 May 18; 9(1). PMID: 42151458.

Published on 4/2/2026

Ryu J, La J, Patell R, Li A, Do N, Brophy M, Fillmore N, Zwicker JI. Survival assessment of warfarin and international normalized ratio exposure in cancer-associated venous thromboembolism: Veterans Affairs healthcare system-based analysis. Haematologica. 2026 Apr 02. PMID: 41924910.

Published on 3/30/2026

Goryachev SD, Wu JT, Lin E, Friedman DR, Zwolinski R, Dhond R, Elbers DC, La J, Yildirim C, Corrigan JK, Chen DCR, Brophy MT, Do NV, Fillmore NR. Rule-based natural language processing to extract clinical trial and research study enrollment history from unstructured notes. Health Informatics J. 2026; 32(1):14604582261430614. PMID: 41912375.

Published on 1/2/2026

Barata PC, Corrigan JK, La J, Culnan JM, Akama-Garren E, Dulberger KN, Dumontier C, Hansen J, Bihn JR, Bitting RL, Brophy MT, Cheng HH, Cooperberg MR, Do NV, Dorff T, Fojo AT, Gaziano JM, Goryachev SD, Halabi S, Hauger RL, Nanus DM, Rebbeck TR, Pan CX, Schoen MW, Swinnerton KN, Myrie K, Ramoni RB, Fillmore NR, Paller CJ, Rettig MB. Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2026 Jan 02; 9(1):e2551231. PMID: 41543856.

Published on 1/1/2026

Cooperberg MR, Bihn JR, Culnan JM, La J, Goryachev SD, Chen DCR, Soloviev O, Lee G, Corrigan JK, Swinnerton KN, Nickols NG, Dulberger KN, Barata P, Bitting RL, Brophy MT, Cheng HH, De Hoedt A, Do NV, Freedland SJ, Garraway IP, Gaziano JM, Halabi S, Hauger RL, Loeb S, Nanus DM, Rebbeck TR, Rettig MB, Pan CX, Myrie K, Ramoni RB, Fillmore NR, Paller CJ. Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance. JAMA Oncol. 2026 Jan 01; 12(1):111-113. PMID: 41264314.